ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00506415
Recruitment Status : Completed
First Posted : July 25, 2007
Results First Posted : September 19, 2012
Last Update Posted : September 19, 2012
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm^2.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Rivastigmine 5 cm^2 Drug: Rivastigmine 10 cm^2 Drug: Rivastigmine 15 cm^2 Drug: Placebo to 15 cm^2 patch Drug: Placebo to 10 cm^2 patch Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1584 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline
Study Start Date : June 2007
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011


Arm Intervention/treatment
Experimental: Open label: Rivastigmine (5 cm^2 / 10 cm^2)
Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
Drug: Rivastigmine 5 cm^2
5 cm^2 transdermal patch
Other Name: Exelon®

Drug: Rivastigmine 10 cm^2
10 cm^2 transdermal patch.
Other Name: Exelon®

Experimental: Double blind: Rivastigmine (10 cm^2)
Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.
Drug: Rivastigmine 10 cm^2
10 cm^2 transdermal patch.
Other Name: Exelon®

Drug: Placebo to 15 cm^2 patch
Placebo of rivastigmine transdermal patch 15 cm^2.

Experimental: Double blind: Rivastigmine (15 cm^2)
Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.
Drug: Rivastigmine 15 cm^2
15 cm^2 transdermal patch.
Other Name: Exelon®

Drug: Placebo to 10 cm^2 patch
Placebo of rivastigmine transdermal patch 10 cm^2.

Experimental: Extended open label Rivastigmine (10 cm^2)
Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
Drug: Rivastigmine 10 cm^2
10 cm^2 transdermal patch.
Other Name: Exelon®




Primary Outcome Measures :
  1. Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period [ Time Frame: Baseline and week 48 of double blind period ]
    The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) subscale comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline.

  2. Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period [ Time Frame: Baseline and week 48 of double blind period ]
    The Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) is a 16 item subscale of the caregiver-based ADCS-IADL scale, developed for the use in dementia studies. The ADCS-IADL total score ranges from 0 to 56, with higher scores indicating less severe impairment. A positive change indicates an improvement from baseline.


Secondary Outcome Measures :
  1. Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period [ Time Frame: 390 days was the maximum ]
    Functional decline was defined by either an at least 1 point decrease in the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) subscale score in a visit and confirmed by the following visit/assessment or at least 2 points decrease from the double blind randomization baseline.

  2. Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period [ Time Frame: Baseline and week 48 of double blind period ]
    Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part A. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. The TMT part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. The score represents the amount of time required to complete the task. Total values for TMT part A range between 0 and 300 seconds. A negative change indicates an improvement from baseline.

  3. Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period [ Time Frame: Baseline and week 48 of double blind period ]
    Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part B. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. TMT has two parts: Part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. Task requirements are similar for TMT-Part B except the person must alternate between numbers and letters. Total values for TMT part B range between 0 and 420 seconds. A negative change from baseline indicates an improvement in condition.

  4. Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period [ Time Frame: Baseline and week 48 of double blind period ]
    Change from baseline to week 48 as assessed by the Neuropsychiatric Inventory (NPI)-10 total score. The scale consists of 10 domains that are rated for both frequency (range 1-4) and severity (range 1-3). A composite score for each domain is calculated (frequency x severity) which ranges from 1 to 12. There is a leading question for each item. If the symptom is not present then the frequency, severity and distress scores are not completed. In this case the score is 0 for the item. The sum of the composite scores yields the NPI-10 total score (range 0-120). A negative change in score indicates an improvement from baseline (symptom reduction).

  5. Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events [ Time Frame: 30 days after a maximum of 96 weeks treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients between 50 and 85 years of age with a diagnosis of probable Alzheimers Disease,
  • Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive,
  • A primary caregiver willing to accept responsibility for supervising treatment, assessing the patient's condition throughout the study, and for providing input into efficacy assessments.
  • For double blind only: Meet the decline criteria of functional (as assessed by the investigator) and cognitive (assessed by a 1 point reduction in Mini-Mental State Examination) score between visits or a 3 point reduction from baseline) decline at weeks 23, 36 or 48.

Exclusion Criteria:

  • Presence of an advanced, severe, progressive, or unstable disease of any type that could interfere with efficacy and safety assessments or put the patient at particular risk,
  • Any medical or neurological condition other than Alzheimers Disease that could explain the patient's dementia,
  • A diagnosis of probable or possible vascular dementia,
  • A current diagnosis of unsuccessfully-treated depression, or any other mental disorder that may interfere with the evaluation of the patient's response to study medication,
  • A history or current diagnosis of cerebrovascular disease (e.g. stroke),
  • A current diagnosis of severe or unstable cardiovascular disease (e.g. unstable coronary artery disease).

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00506415


  Hide Study Locations
Locations
United States, Alabama
Novartis investigative site
Birmingham, Alabama, United States, 35294
United States, Arizona
Novartis investigative site
Gilbert, Arizona, United States, 85234
Novartis investigative site
Phoenix, Arizona, United States, 85004
Novartis investigative site
Sun City, Arizona, United States, 85351
United States, California
Novartis investigative site
Anaheim, California, United States, 92804
Novartis investigative site
Carson, California, United States, 90746
Novartis investigative site
Costa Mesa, California, United States, 92626
Novartis investigative site
Fullerton, California, United States, 92835
Novartis investigative site
La Habra, California, United States, 90631
Novartis investigative site
La Jolla, California, United States, 92037
Novartis investigative site
National City, California, United States, 91950
Novartis investigative site
Redlands, California, United States, 92374
Novartis investigative site
San Francisco, California, United States, 94115
United States, Colorado
Novartis investigative site
Fort Collins, Colorado, United States, 80524
Novartis investigative site
Longmont, Colorado, United States, 80501
United States, Florida
Novartis investigative site
Boca Raton, Florida, United States, 33431
Novartis investigative site
Bradenton, Florida, United States, 32405
Novartis investigative site
Deerfield Beach, Florida, United States, 33064
Novartis investigative site
Delray Beach, Florida, United States, 33445
Novartis investigative site
Fort Lauderdale, Florida, United States, 33308
Novartis investigative site
Gainesville, Florida, United States, 32610
Novartis investigative site
Miami Beach, Florida, United States, 33140
Novartis investigative site
Pompano Beach, Florida, United States, 33060
Novartis investigative site
Port Charlotte, Florida, United States, 33952
Novartis investigative site
Sunrise, Florida, United States, 33351
Novartis investigative site
West Palm Beach, Florida, United States, 33407
United States, Georgia
Novartis investigative site
Atlanta, Georgia, United States, 30341-4155
Novartis investigative site
Macon, Georgia, United States, 31201
United States, Hawaii
Novartis Investigative Site
Honolulu, Hawaii, United States, 96817
United States, Illinois
Novartis investigative site
Chicago, Illinois, United States, 60611
United States, Massachusetts
Novartis investigative site
Springfield, Massachusetts, United States, 01104
United States, Michigan
Novartis investigative site
Flint, Michigan, United States, 48532
Novartis investigative site
Flushing, Michigan, United States, 48433
Novartis investigative site
Roseville, Michigan, United States, 48066
Novartis investigative site
Traverse City, Michigan, United States, 49684-2340
United States, Mississippi
Novartis investigative site
Hattiesburg, Mississippi, United States, 39401
Novartis investigative site
Ocean Springs, Mississippi, United States, 39564
United States, Missouri
Novartis investigative site
Columbia, Missouri, United States, 65201
Novartis investigative site
St. Louis, Missouri, United States, 63141
United States, New Jersey
Novartis investigative site
Flemington, New Jersey, United States, 08822
Novartis investigative site
Nutley, New Jersey, United States, 07110
Novartis investigative site
Somerset, New Jersey, United States, 08873
United States, New York
Novartis investigative site
Albany, New York, United States, 12208
Novartis investigative site
Syracuse, New York, United States, 13210-1853
United States, North Carolina
Novartis investigative site
Greensboro, North Carolina, United States, 27401
Novartis investigative site
Morganton, North Carolina, United States, 28655
Novartis investigative site
Winston-Salem, North Carolina, United States, 27103-4019
Novartis investigative site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Novartis investigative site
Canton, Ohio, United States, 44718
Novartis investigative site
Columbus, Ohio, United States, 43220
United States, Oregon
Novartis investigative site
Corvallis, Oregon, United States, 97330
Novartis investigative site
Portland, Oregon, United States, 97225
United States, Pennsylvania
Novartis investigative site
Beaver, Pennsylvania, United States, 15009-1957
Novartis investigative site
Erie, Pennsylvania, United States, 16506
Novartis investigative site
Greensburg, Pennsylvania, United States, 15601
Novartis investigative site
Pittsburgh, Pennsylvania, United States, 15243
United States, South Carolina
Novartis investigative site
Beaufort, South Carolina, United States, 29902
Novartis investigative site
Summerville, South Carolina, United States, 29485
United States, Tennessee
Novartis investigative site
Brentwood, Tennessee, United States, 37027-5240
Novartis investigative site
Nashville, Tennessee, United States, 37203
United States, Texas
Novartis investigative site
Dallas, Texas, United States, 75231
Novartis investigative site
Fort Worth, Texas, United States, 76107
Novartis investigative site
Irving, Texas, United States, 75062
United States, West Virginia
Novartis investigative site
Charleston, West Virginia, United States, 25304
Novartis investigative site
Huntington, West Virginia, United States, 25701
Canada, Ontario
Novartis investigative site
Toronto, Ontario, Canada
Canada
Novartis investigative site
Calgary, Canada
Novartis investigative site
Edmonton, Canada
Novartis investigative site
Greenfield Park, Canada
Novartis investigative site
Halifax, Canada
Novartis investigative site
London, Canada
Novartis investigative site
Montreal, Canada
Novartis investigative site
Ottawa, Canada
Novartis investigative site
Peterborough, Canada
Novartis investigative site
Quebec, Canada
Novartis investigative site
Regina, Canada
Novartis investigative site
Toronto, Canada
Novartis investigative site
Vancouver, Canada
Novartis investigative site
Winnipeg, Canada
France
Novartis investigative site
Fains Veel, Alsace Lorraine, France
Novartis investigative site
Dijon, Burgundy, France
Novartis investigative site
Reims, Champagne-Ardenne, France
Novartis investigative site
Bordeaux, France
Novartis investigative site
Bourg en Bresse, France
Novartis investigative site
Caen, France
Novartis investigative site
Cherbourg, France
Novartis investigative site
Dijon, France
Novartis investigative site
Limoges, France
Novartis investigative site
Montpellier, France
Novartis investigative site
Nice, France
Novartis investigative site
Paris, France
Novartis investigative site
Rennes, France
Novartis investigative site
Rodez, France
Germany
Novartis investigative site
Bad Neustadt/Saale, Germany
Novartis investigative site
Berlin, Germany
Novartis investigative site
Bonn, Germany
Novartis investigative site
Burg, Germany
Novartis investigative site
Duesseldorf, Germany
Novartis investigative site
Frankfurt, Germany
Novartis investigative site
Giessen, Germany
Novartis investigative site
Koln, Germany
Novartis investigative site
Krefeld, Germany
Novartis investigative site
Leipzig, Germany
Novartis investigative site
Magdeburg, Germany
Novartis investigative site
Mannheim, Germany
Novartis investigative site
Marburg, Germany
Novartis investigative site
Muenchen, Germany
Novartis investigative site
Muenster, Germany
Novartis investigative site
Nuernberg, Germany
Novartis investigative site
Stralsund, Germany
Novartis investigative site
Stuttgart, Germany
Novartis investigative site
Wurzburg, Germany
Italy
Novartis investigative site
Milano, Milan, Italy
Novartis investigative site
Ancona, Italy
Novartis investigative site
Arcugnano, Italy
Novartis investigative site
Arezzo, Italy
Novartis investigative site
Bari, Italy
Novartis investigative site
Bologna, Italy
Novartis investigative site
Brescia, Italy
Novartis investigative site
Cagliari, Italy
Novartis investigative site
Catania, Italy
Novartis investigative site
Città di Castello, Italy
Novartis investigative site
Cremona, Italy
Novartis investigative site
Ferrara, Italy
Novartis investigative site
Firenze, Italy
Novartis investigative site
Foggia, Italy
Novartis investigative site
Genova, Italy
Novartis investigative site
La Spezia, Italy
Novartis investigative site
Milano, Italy
Novartis investigative site
Milan, Italy
Novartis investigative site
Modena, Italy
Novartis investigative site
Napoli, Italy
Novartis investigative site
Padova, Italy
Novartis investigative site
Pavia, Italy
Novartis investigative site
Perugia, Italy
Novartis investigative site
Pisa, Italy
Novartis investigative site
Rho, Italy
Novartis investigative site
Rome, Italy
Novartis investigative site
Torino, Italy
Novartis investigative site
Verona, Italy
Spain
Novartis investigative site
Barcelona, Spain
Novartis investigative site
Palma de Mallorca, Spain
Switzerland
Novartis investigative site
Basel, Switzerland
Novartis investigative site
Biel, Switzerland
Novartis investigative site
Mendrisio, Switzerland
Sponsors and Collaborators
Novartis Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00506415     History of Changes
Other Study ID Numbers: CENA713D2340
First Posted: July 25, 2007    Key Record Dates
Results First Posted: September 19, 2012
Last Update Posted: September 19, 2012
Last Verified: September 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Alzheimer's
Patch
Cognitive
Decline

Additional relevant MeSH terms:
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Rivastigmine
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents